Nasdaq GlobeNewswire

RedHill Biopharma Announces Proposed Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants

Del

TEL-AVIV, Israel, 2016-12-20 22:01 CET (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that it intends to offer its American Depositary Shares (“ADSs”), each representing ten of its ordinary shares, and warrants to purchase ADSs, concurrently in an underwritten public offering and in a registered direct offering. RedHill also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the securities offered to the public in the underwritten public offering. Both offerings are subject to market conditions and there can be no assurance as to whether or when the offerings may be completed, or as to the actual size or terms of the offerings.

The Company intends to use the proceeds from both offerings to fund clinical development programs, for potential acquisitions, to support commercial operations and for general corporate purposes.

Roth Capital Partners is acting as the sole book-running manager and Echelon Wealth Partners is acting as Canadian manager for the underwritten public offering with respect to sales in Canada.  Roth Capital Partners is acting as placement agent in the registered direct offering.

The ADSs and warrants will be issued pursuant to a shelf registration statement that was previously filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

This offering will be made only by means of a prospectus. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, by contacting Roth Capital Partners, Attention: Equity Capital Markets, 888 San Clemente Drive, Newport Beach, CA 92660, or by telephone at 800-678-9147, or by email at RothECM@roth.com

About RedHill Biopharma Ltd.:
RedHill Biopharma Ltd. (NASDAQ/TASE: RDHL) is a biopharmaceutical company headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill’s pipeline of proprietary products includes: (i) RHB-105 - an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study; (ii) RHB-104 - an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study and a completed proof-of-concept Phase IIa study for multiple sclerosis; (iii) BEKINDA® (RHB-102)- a once-daily oral pill formulation of ondansetron with an ongoing Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; (iv) RHB-106 - an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVA® (ABC294640) - a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON - a Phase II-stage first-in-class, orally-administered uPA inhibitor, targeting gastrointestinal and other solid tumors and (vii) RIZAPORT® (RHB-103) - an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in Germany in October 2015.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to establish and maintain corporate collaborations; (vi) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (vii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and of the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (viii) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (ix) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (x) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xi) estimates of the Company’s expenses, future revenues capital requirements and the Company’s needs for additional financing; (xii) competitive companies and technologies within the Company’s industry; and (xiii) the impact of the political and security situation in Israel on the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on February 25, 2016. All forward-looking statements included in this Press Release are made only as of the date of this Press Release. We assume no obligation to update any written or oral forward-looking statement unless required by law.

         Company contact:
         Adi Frish
         Senior VP Business Development & Licensing
         RedHill Biopharma
         +972-54-6543-112
         adi@redhillbio.com
         
         IR contact (U.S.):
         Marcy Nanus
         Senior Vice President
         The Trout Group
         +1-646-378-2927
         Mnanus@troutgroup.com

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

InnovMetric Acquires Prefixa Vision Systems21.2.2018 21:22Pressemelding

Consolidates its market presence in Mexico QUEBEC CITY, Feb. 21, 2018 (GLOBE NEWSWIRE) -- InnovMetric Software Inc., the leading provider of universal 3D metrology software solutions, today announced the acquisition of Prefixa Vision Systems, its PolyWorks® Master distributor in Mexico, following five years of successful cooperation. "The growth of the automotive industry in Mexico has been so phenomenal in recent years that in our latest fiscal year Mexico became the 5th largest PolyWorks market in the world. InnovMetric is deeply committed to expanding its local technical expertise to assist its Mexican customers in their successful migration to the PolyWorks universal 3D metrology software platform," said Marc Soucy, President of InnovMetric. The acquisition allows InnovMetric to expand the capabilities of its local subsidiary, PolyWorks Mexico, which include supporting and training Mexican customers and assisting local metrology hardware partners. PolyWorks Mexico will also market

Taconic Biosciences Announces the Formation of Scientific Advisory Board21.2.2018 19:13Pressemelding

RENSSELAER, N.Y., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, announced the formation of its Scientific Advisory Board (SAB) with the initial appointments of J. Victor Garcia, PhD, Andrew Goodman, PhD, and David Hill, PhD. The SAB will collaborate with Taconic's management in providing scientific insight and guidance on the evolution of the company's product and service portfolios. Capitalizing on Taconic's existing leadership in both the microbiome and immuno-oncology spaces, the SAB members bring complementary expertise to continue to drive innovation in these and other research areas. "Discovery and pre-clinical animal models continue to move toward highly-complex and high-value translational models. To continue to provide the best solutions for our customers, it is essential for Taconic to have guidance from prominent scientific experts as we develop and validate new models and services," sha

SD-WAN Market Leader Aryaka Further Expands UK and EMEA Market Reach with Intergence Partnership21.2.2018 16:01Pressemelding

Partnership Enables More UK and EMEA Enterprises to Adopt Global SD-WAN as-a-Service LONDON, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, today announced that Cambridge, UK-based Intergence will deploy Aryaka's global SD-WAN solution to enhance global connectivity and application performance for its enterprise customers with offices in the UK and Europe. Partnering with Aryaka strengthens Intergence's infrastructure services proposition for its global enterprise customers. Intergence comprises a team of IT infrastructure experts that help organizations realize their digital transformation objectives. Formed in 2003, the company uses innovative technologies like its Stratiam(TM) solution to provide CIOs with insights about IT performance and the customer's digital experiences, and to simplify complex IT problems. Intergence's infrastructure services provide IT leaders with greater flexibility, agility, and cost efficiency. The partnership will enable In

TrueCommerce Dynamics 365 Solution Featured on Microsoft AppSource21.2.2018 16:00Pressemelding

TrueCommerce Solution Delivers Powerful Supply Chain Integration Capabilities to Dynamics 365 Community PITTSBURGH, Feb. 21, 2018 (GLOBE NEWSWIRE) -- TrueCommerce, a global provider of trading partner connectivity and integration solutions, has announced today that its Microsoft Dynamics 365 solution is available on Microsoft AppSource. Built exclusively for and within the native Dynamics 365 platform, the embedded solution connects directly with TrueCommerce's global commerce network, offering immediate access to more than 92,000 pre-connected retailers, marketplaces, distributors, vendors and logistics providers. "Our solution for Dynamics 365 offers a multi-company, multi-deployment architecture that scales to support complex enterprise requirements," said TrueCommerce president Ross Elliott. "We are excited to be selected as one of the few EDI solutions to be featured on Microsoft AppSource, recognition of having achieved Microsoft's highest standards for quality and reliability fo

Colliers International Named to IAOP® Global Outsourcing 100 List for 13th Consecutive Year21.2.2018 15:00Pressemelding

International Association of Outsourcing Professionals® Honors Colliers in Its Annual Listing of the World's Best Outsourcing Service Providers TORONTO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Leading global commercial real estate services firm Colliers International Group Inc. (NASDAQ:CIGI) (TSX:CIGI) is pleased to announce that it has again been selected for The 2018 Global Outsourcing 100 list by IAOP®, an honor the company has earned for 13 straight years, more than any other real estate services provider. Colliers has been named to the list each year since its inception. Colliers is committed to leadership in the global outsourcing industry and has a proven track-record in the space. The company's outstanding growth continues through a focus on maintaining the most collaborative and creative culture in the industry, allowing clients to accelerate their success by sharing its market-leading expertise. "We are honored to again receive this prestigious recognition from IAOP," said Dylan Ta

Announcing North America's Most Advanced Radio Access Network Solution by GCI in Collaboration with Altiostar21.2.2018 15:00Pressemelding

ANCHORAGE, Alaska, Feb. 21, 2018 (GLOBE NEWSWIRE) -- GCI, Alaska's largest telecommunications provider announced today that it has selected Altiostar to supply virtualized RAN (vRAN) technology to support GCI's LTE-Advanced network deployment and to lay the foundation for 5G and IoT. The technology will allow GCI to expand network coverage and improve capacity, and thus enhance end-user experience. Over the last 12 months GCI has been conducting field trials in Anchorage and Fairbanks with this solution from Altiostar, and this contract award is the result of this validation of the vRAN technology. Altiostar will introduce its LTE-Advanced technologies such as 4x4 MIMO and Multi-band Carrier Aggregation to significantly enhance end user experience for data applications and better voice quality using Voice over LTE (VoLTE). LTE 4x4 MIMO enables better mobile broadband coverage and data throughput for GCI subscribers, and increased spectral efficiency for GCI. GCI customers will benefit

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom